drugset / Trial / NCT05545436
Carrelizumab (PD-1) Combined With Chemotherapy in Neoadjuvant Treatment of Locally Advanced Gastric Cancer
Phase 2
Unknown
34 enrolled
Third Affiliated Hospital, Sun Yat-Sen University
Jiangsu Hengrui Pharmaceutical Co., Ltd. · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a single-arm, open, exploratory clinical study to evaluate the efficacy of carrelizumab (PD-1) combined with chemotherapy (SOX/XELOX) as neoadjuvant therapy and to observe the changes of tumor immune microenvironment in patients with locally advanced gastric or gastroesophageal junction cancer (T3-4NXM0).
Timeline
- Start
- 2022-09-20
- Primary completion
- 2022-12
- Completion
- 2023-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Camrelizumab | Monoclonal antibody | 200 mg | — |
| Background | Capecitabine | Small molecule | 1000 mg/m2 | — |
| Background | Oxaliplatin | Small molecule | 130 mg/m2 | — |
| Background | Teggio | Unknown | 40 mg/m2 | — |